A CAUSE FOR CELEBRATION

Your first look at Emgality, now approved for the preventive treatment of migraine in adults.[1]

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

PROGRAM INFORMATION

GETTING TO NOW: THE ROAD TO CGRP THERAPY

Thursday, December 13, 2018

6:30 PM

Speaker

Stephen Landy, MD

Location

Chandelier
575 S. Royal St.
Jackson, Tennessee 38305

RSVP

Gary Edwards
edwards_gary_lee@lilly.com
731-499-1581

1. Emgality [Prescribing Information], Indianapolis, IN Lilly USA, LLC.

Please see Important Safety Information on the next page, and please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the pen and prefilled syringe.

Emgality™ (galcanezumab-gnlm) 120 mg injection

Join us!

For over 140 years, Eli Lilly and Company has been researching medications and serving patients. We're excited to share some of the results of these efforts at the program.

Learn More About

- The role of calcitonin gene-related peptide (CGRP) in migraine
- The results of the phase 3 clinical trial program
- The mechanism of action (MOA)
- Dosing information
- Safety information
- Savings and support*

This will give you the opportunity to ask a headache specialist questions in person, and to catch up with your peers.

INDICATION

Emgality is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Warnings and Precautions

Hypersensitivity Reactions

Hypersensitivity reactions (e.g., rash, urticaria, and dyspnea) have been reported with Emgality in clinical studies. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

Adverse Reactions

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the pen and prefilled syringe.

GZ HCP ISI 27SEP2018

*Commercially insured patients only; not for government beneficiaries.

1. Emgality [Prescribing Information], Indianapolis, IN Lilly USA, LLC.

As a result of enacted state and federal legislation, if you are a prescriber or other licensed healthcare professional with an active license from MA, MN, and/or VT, a Veterans Affairs employee, and/or a state government employee, you may be restricted from accepting industry-provided food/beverage and/or educational item(s). Please consult your state or federal regulations or ethics laws.

This program is intended only for invited healthcare professionals (HCPs) or other appropriate personnel for whom the information that is being presented will be relative to their practice. We regret that spouses or other guests cannot be accommodated.

This program is sponsored by and the speaker is presenting on behalf of Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.

Emgality™ (galcanezumab-gnlm) 120 mg injection

Lilly